Inherited Susceptibility to Uterine Leiomyomas and Renal Cell Cancer

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Mar 15

PMID 11248088

Citations 212

Authors

V Launonen

O Vierimaa

M Kiuru

J Isola

S Roth

E Pukkala

P Sistonen

R Herva

L A Aaltonen

Affiliations

Soon will be listed here.

Abstract

Herein we report the clinical, histopathological, and molecular features of a cancer syndrome with predisposition to uterine leiomyomas and papillary renal cell carcinoma. The studied kindred included 11 family members with uterine leiomyomas and two with uterine leiomyosarcoma. Seven individuals had a history of cutaneous nodules, two of which were confirmed to be cutaneous leiomyomatosis. The four kidney cancer cases occurred in young (33- to 48-year-old) females and displayed a unique natural history. All these kidney cancers displayed a distinct papillary histology and presented as unilateral solitary lesions that had metastasized at the time of diagnosis. Genetic-marker analysis mapped the predisposition gene to chromosome 1q. Losses of the normal chromosome 1q were observed in tumors that had occurred in the kindred, including a uterine leiomyoma. Moreover, the observed histological features were used as a tool to diagnose a second kindred displaying the phenotype. We have shown that predisposition to uterine leiomyomas and papillary renal cell cancer can be inherited dominantly through the hereditary leiomyomatosis and renal cell cancer (HLRCC) gene. The HLRCC gene maps to chromosome 1q and is likely to be a tumor suppressor. Clinical, histopathological, and molecular tools are now available for accurate detection and diagnosis of this cancer syndrome.

Citing Articles

Metabolic tumor parameters on F-FDG PET/CT can predict the expression of PD-L1 and prognosis in patients with fumarate hydratase-deficient renal cell carcinoma.

Huang S, Zhang Y, Zhang W, Tian T, Dai H, Qi M Ann Nucl Med. 2025; .

PMID: 40088403 DOI: 10.1007/s12149-025-02039-2.

Implications of Fumarate Hydratase Deficiency (FHD) and Cancer Risk: A Window into the Clinical and Oncological Implications of a Rare Disorder in Gynecology.

DIndinosante M, Lardino S, Bruno M, Stabile G, Pavone M, Giannone G Cancers (Basel). 2025; 17(4).

PMID: 40002168 PMC: 11852715. DOI: 10.3390/cancers17040573.

Hereditary leiomyomatosis and renal cell cancer (HLRCC), pheochromocytoma (PCC)/paraganglioma (PGL) and germline fumarate hydratase (FH) variants.

Orrego J, Chorny J Endocrinol Diabetes Metab Case Rep. 2024; 2024(4.

PMID: 39705504 PMC: 11737469. DOI: 10.1530/EDM-24-0073.

Fumarate Hydratase-Deficient Leiomyoma with Double Mutation Sites in the FH : A Rare Case Report and Literature Review.

Wei G, Chen J, Gong X, Zhang D Int J Womens Health. 2024; 16:2137-2141.

PMID: 39677552 PMC: 11640030. DOI: 10.2147/IJWH.S444069.

The skeleton: an overlooked regulator of systemic glucose metabolism in cancer?.

Ronghe R, Tavares A Front Oncol. 2024; 14:1481241.

PMID: 39588310 PMC: 11586348. DOI: 10.3389/fonc.2024.1481241.

References

Reuter V, Presti Jr J . Contemporary approach to the classification of renal epithelial tumors. Semin Oncol. 2000; 27(2):124-37. View

Walther M, Choyke P, Glenn G, Lyne J, Rayford W, Venzon D . Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999; 161(5):1475-9. DOI: 10.1016/s0022-5347(05)68930-6. View

Lynch H, Lynch J . Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol. 2000; 18(4):305-13. DOI: 10.1002/(sici)1098-2388(200006)18:4<305::aid-ssu5>3.0.co;2-a. View

Malchoff C, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V . Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab. 2000; 85(5):1758-64. DOI: 10.1210/jcem.85.5.6557. View

Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View

REED W, Walker R, Horowitz R . Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol. 1973; 53(5):409-16. DOI: 102340/0001555553409416. View

Cohen A, Li F, Berg S, Marchetto D, Tsai S, Jacobs S . Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979; 301(11):592-5. DOI: 10.1056/NEJM197909133011107. View

Latif F, Tory K, Gnarra J, Yao M, Duh F, Orcutt M . Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993; 260(5112):1317-20. DOI: 10.1126/science.8493574. View

Cottingham Jr R, Idury R, Schaffer A . Faster sequential genetic linkage computations. Am J Hum Genet. 1993; 53(1):252-63. PMC: 1682239. View

10.

Teppo L, Pukkala E, Lehtonen M . Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol. 1994; 33(4):365-9. DOI: 10.3109/02841869409098430. View

11.

Yeung R, Xiao G, Jin F, Lee W, Testa J, Knudson A . Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci U S A. 1994; 91(24):11413-6. PMC: 45241. DOI: 10.1073/pnas.91.24.11413. View

12.

Hino O, Fukuda T, Satake N, Kobayashi T, Honda S, Orimoto K . TSC2 gene mutant (Eker) rat model of a Mendelian dominantly inherited cancer. Prog Exp Tumor Res. 1999; 35:95-108. DOI: 10.1159/000062006. View

13.

Lubensky I, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N . Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999; 155(2):517-26. PMC: 1866853. DOI: 10.1016/S0002-9440(10)65147-4. View

14.

Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O . A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet. 1995; 9(1):70-4. DOI: 10.1038/ng0195-70. View

15.

Everitt J, Wolf D, Howe S, Goldsworthy T, Walker C . Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol. 1995; 146(6):1556-67. PMC: 1870902. View

16.

Rohde K, Teare M, Scherneck S, Santibanez Koref M . A program using loss-of-constitutional-heterozygosity data to ascertain the location of predisposing genes in cancer families. Hum Hered. 1995; 45(6):337-45. DOI: 10.1159/000154302. View

17.

Kruglyak L, Daly M, Lander E . Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet. 1996; 58(6):1347-63. PMC: 1915045. View

18.

Teh B, Giraud S, Sari N, Hii S, Bergerat J, Larsson C . Familial non-VHL non-papillary clear-cell renal cancer. Lancet. 1997; 349(9055):848-9. DOI: 10.1016/S0140-6736(05)61751-5. View

19.

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

20.

Delahunt B, Eble J . Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997; 10(6):537-44. View